All In Biotech

Drug Trial Radar · NCT06047184

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

A Phase I, Open, Multicenter Study of BEBT-209 in Women With Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

100

Actual

Start

Jul 15, 2019

Primary completion

Jan 30, 2024

Study completion Jan 30, 2024

Sponsor

Lead sponsor
BeBetter Med IncIndustry
Sponsor type
Industry
Collaborators
Hunan Cancer Hospital; Xiangya Hospital of Central South University
First posted
Sep 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study includes a dose escalation trial of BEBT-209 monotherapy in HR +/HER2- advanced breast cancer patients and a Phase 1b trial of BEBT-209 as a single therapy, in combination with letrozole, and in combination with fulvestrant in ER +/HER2- advanced breast cancer in women. To evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BEBT-209 as a single therapy, in combination with letrozole, and in combination with fulvestrant. To determine the recommended dose for late clinical studies of monotherapy or combination therapy in patients with HR +/HER2- advanced breast cancer.

Conditions

  • Advanced Breast Cancer

Interventions

  • BEBT-209 capsulesDrug

    BEBT-209 capsules, 25mg once daily, or 25mg, 50mg, 75mg, 100mg, 150mg each time, twice daily, were administered continuously for 3 weeks and discontinued for 1 week, and 4 weeks were used as a treatment cycle.

  • Letrozole tabletsDrug

    Letrozole tablets, 2.5mg each time, once a day for 4 weeks, 4 weeks as a treatment cycle.

  • FulvestrantDrug

    Fulvestrant, injection, 500mg each time, 1 time on day 1 and day 15 of the first cycle, and once on the first day of each cycle from the second cycle, 4 weeks as a treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTDTime frame: 4 weeks
  2. DLTTime frame: 4 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.